Roar Nissen-Meyer

Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials

Rosie Bradley, Jeremy Braybrooke, Mike J Clarke, Robert K. Hills et autres

BACKGROUND: For premenopausal women with oestrogen receptor (ER)-positive early breast cancer, the additional protective effect of ovarian function suppression (OFS, by ablation or drugs) may depend on menopausal status after any chemotherapy, and tamoxifen usage. We assess the effects of OFS on …

«Prophylaktische» Ovarektomie und Bestrahlung der Ovarien bei Mammakarzinom

Roar Nissen-Meyer

Perioperative Adjuvant Chemotherapy of Breast Cancer: The Scandinavian Experience

Roar Nissen-Meyer, Herman Høst, Kjell Kjellgren, Bengt Å. Månsson et autres

no (code pays fourni par la source)

Primary breast cancer: The effect of primary ovarian irradiation

Roar Nissen-Meyer

no (code pays fourni par la source)

Is There a Role for Perioperative Adjuvant Cytotoxic Therapy in the Treatment of Early Breast Cancer?

J. Houghton, Michael S. Baum, Roar Nissen-Meyer, Diana Riley et autres

gb, no (code pays fourni par la source)

Perioperative Adjuvant Chemotherapy in Breast Cancer: The Scandinavian Adjuvant Chemotherapy Study 1

Kjell Kjellgren, Roar Nissen-Meyer, Torsten Norin

In a randomized study of operable primary breast cancer patients initiated January 1965, 507 patients received one single course with cyclophosphamide 5 mg/kg/day for six days, first dose given immediately after mastectomy. The 519 control patients received no adjuvant chemotherapy. In other …

Prolonged Adjuvant Chemotherapy in Breast Cancer: The Scandinavian Adjuvant Chemotherapy Study 2

Roar Nissen-Meyer, Herman Høst, K. Kjellcren

Eleven hundred and sixteen primary female breast cancer patients received one short perioperative chemotherapy course. The node negative patients were randomised between immunotherapy (corynebacterium parvum s.c. around the scar 2 weeks after mastectomy), or no further adjuvant therapy. A moderate, but significant …

Adjuvant Immunotherapy in Node-Negative Patients: Results of a Scandinavian Study

Roar Nissen-Meyer, Herman Høst, Kjell Kjellgren

no (code pays fourni par la source)

Is there a role for perioperative adjuvant therapy in the treatment of early breast cancer?

J. Houghton, Mike Baum, Roar Nissen-Meyer

Despite having been investigated for many years, the role of adjuvant perioperative chemotherapy in the treatment of early breast cancer has still to be fully defined. This paper reviews the early trials of perioperative cytotoxic therapy and overviews the two largest trials; …

gb (code pays fourni par la source)

Treatment of node-negative breast cancer patients with short course of chemotherapy immediately after surgery.

Roar Nissen-Meyer, Herman Høst, Kjell Kjellgren, Bengt Å. Månsson et autres

In our first study, one short course of chemotherapy (cyclophosphamide, 5 mg/kg/day for 6 days iv) was given perioperatively to 507 patients with operable primary breast cancer; there were 519 control subjects. Randomization was done by telephone from the operating theater, and …

Short Perioperative Versus Long-Term Adjuvant Chemotherapy

Roar Nissen-Meyer, Herman Høst, Kjell Kjellgren, Bengt Å. Månsson et autres

no (code pays fourni par la source)

Second Malignant Neoplasms in Operable Carcinoma of the Breast

E. E. Holdener, Roar Nissen-Meyer, Gianni Bonadonna, Steven Jones et autres

ch (code pays fourni par la source)